|
Myeloid Leukemia, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
|
31826340 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that ABL and AXL inhibitors might be effective against brain metastases.
|
31825826 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Then the HFD-induced NAFLD mice were treated with vitamin D. Next, the serum levels of TNF-α, GSH-px and malondialdehyde (MDA) were assessed using ELISA and ROS content was evaluated by flow cytometry, followed by the measurement of expression of Duox1, Duox2, SOD1, SOD2, PRDX1 I, ACC, SREBP1c, MTTP, PPARα, p53, p21 and p16 using RT-qPCR and Western blot analysis.
|
31756344 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
|
31666936 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
|
31666936 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.
|
31601692 |
2019 |
|
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There have been successful examples of targeted therapy improving the outcome of some childhood cancers, such as the addition of an ABL class tyrosine kinase inhibitor to conventional chemotherapy substantially improving the cure rate for patients with BCR-ABL1 positive acute lymphoblastic leukemia.
|
31563145 |
2020 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
There have been successful examples of targeted therapy improving the outcome of some childhood cancers, such as the addition of an ABL class tyrosine kinase inhibitor to conventional chemotherapy substantially improving the cure rate for patients with BCR-ABL1 positive acute lymphoblastic leukemia.
|
31563145 |
2020 |
|
Familial hypercholesterolemia - homozygous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
|
31403880 |
2020 |
|
Cardiovascular Diseases
|
0.050 |
Biomarker
|
group |
BEFREE |
The structure of MTP presented here gives important insights into the potential mechanisms of action of this essential lipid transfer molecule, structure-based rationale for previously reported disease-causing mutations, and a means for rational drug design against cardiovascular disease and obesity.
|
31395737 |
2019 |
|
Obesity
|
0.040 |
Biomarker
|
disease |
BEFREE |
The structure of MTP presented here gives important insights into the potential mechanisms of action of this essential lipid transfer molecule, structure-based rationale for previously reported disease-causing mutations, and a means for rational drug design against cardiovascular disease and obesity.
|
31395737 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology) study involving patients with advanced/metastatic solid cancer who had exhausted therapeutic options and who were offered MTP in order to identify cognate therapies.
|
31366375 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology) study involving patients with advanced/metastatic solid cancer who had exhausted therapeutic options and who were offered MTP in order to identify cognate therapies.
|
31366375 |
2019 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
MTTP-AS1-Long is mainly in the liver and is in the cytoplasm of human hepatoma cells.MTTP-AS1-Short is in the testis.
|
31353085 |
2019 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
MTTP-AS1-Long is mainly in the liver and is in the cytoplasm of human hepatoma cells.MTTP-AS1-Short is in the testis.
|
31353085 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
|
31349760 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of tyrosine kinase inhibitors (TKIs) targeting the ABL kinase (such as imatinib) has dramatically improved survival of CML and Ph+ ALL patients.
|
31349760 |
2019 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
|
31349760 |
2019 |
|
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of tyrosine kinase inhibitors (TKIs) targeting the ABL kinase (such as imatinib) has dramatically improved survival of CML and Ph+ ALL patients.
|
31349760 |
2019 |
|
Fatty Liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MTTP polymorphisms and hepatic steatosis in individuals chronically infected with hepatitis C virus.
|
31321587 |
2019 |
|
Steatohepatitis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MTTP polymorphisms and hepatic steatosis in individuals chronically infected with hepatitis C virus.
|
31321587 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MTTP polymorphisms and hepatic steatosis in individuals chronically infected with hepatitis C virus.
|
31321587 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL<sup>+</sup> human leukemia".
|
31316004 |
2019 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL<sup>+</sup> human leukemia".
|
31316004 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
|
31316003 |
2019 |